DiaMedica Therapeutics
DMAC
57 hedge funds and large institutions have $28.5M invested in DiaMedica Therapeutics in 2025 Q1 according to their latest regulatory filings, with 14 funds opening new positions, 20 increasing their positions, 10 reducing their positions, and 2 closing their positions.
600% more first-time investments, than exits
New positions opened: 14 | Existing positions closed: 2
533% more call options, than puts
Call options by funds: $57K | Put options by funds: $9K
100% more repeat investments, than reductions
Existing positions increased: 20 | Existing positions reduced: 10
27% more funds holding
Funds holding: 45 → 57 (+12)
1.8% more ownership
Funds ownership: 15.74% → 17.53% (+1.8%)
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
22% less capital invested
Capital invested by funds: $36.5M → $28.5M (-$8.06M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Millennium Management
New York
|
+$1.44M |
| 2 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$1.04M |
| 3 |
Royal Bank of Canada
Toronto,
Ontario, Canada
|
+$885K |
| 4 |
Vanguard Group
Malvern,
Pennsylvania
|
+$625K |
| 5 |
PAPAIJV
Paragon Associates & Paragon Associates II Joint Venture
Dallas,
Texas
|
+$487K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
First Manhattan
New York
|
-$1.33M |
| 2 |
6CM
683 Capital Management
New York
|
-$413K |
| 3 |
Qube Research & Technologies (QRT)
London,
United Kingdom
|
-$331K |
| 4 |
Citigroup
New York
|
-$124K |
| 5 |
SSA
Schonfeld Strategic Advisors
New York
|
-$55K |
DMAC Hedge Fund Activity: Q1 2025 in Review
57 of the 7,458 institutional investors tracked by Wall St. Rank reported a position in DiaMedica Therapeutics (DMAC) for Q1 2025, worth a combined $28.5M — down 22% from $36.5M a quarter earlier.
Buyers outnumbered sellers: 14 funds opened new DMAC positions and 2 closed out — a net gain of 12 holders — while 20 added to existing stakes and 10 trimmed.
The largest buyer was Millennium Management, adding an estimated $1.44M. The largest seller was First Manhattan, cutting an estimated $1.33M.
- 57 institutional investors held DiaMedica Therapeutics (DMAC) as of Q1 2025, up from 45 in Q4 2024.
- Funds reported $28.5M of DiaMedica Therapeutics stock for Q1 2025, down 22% quarter-over-quarter.
- 14 funds opened new DiaMedica Therapeutics positions in Q1 2025 and 2 closed out, a net change of +12 holders.
- The largest DiaMedica Therapeutics buyer in Q1 2025 was Millennium Management, an estimated $1.44M added.
- The largest DiaMedica Therapeutics seller in Q1 2025 was First Manhattan, an estimated $1.33M sold.
Based on aggregated 13F filings for Q1 2025.